Biased ligands: Pathway validation for novel GPCR therapeutics

Current Opinion in Pharmacology

Volumn 16, Issue 1, 2014, Pages 108-115

  Rominger, David H ^a   Cowan, Conrad L ^a   Gowen Macdonald, William ^a   Violin, Jonathan D ^a  

^a TREVENA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; KAPPA OPIATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MU OPIATE RECEPTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; LIGAND;

ARTICLE; BIOACCUMULATION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; VALIDATION PROCESS; ANIMAL; DRUG DEVELOPMENT; METABOLISM;

ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84900498728     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.04.002     Document Type: Review

References (69)

1. S. Moro, G. Spalluto, and K.A. Jacobson Techniques Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example Trends Pharmacol Sci 26 2005 44 51
2. L.Q. Jin, H.Y. Wang, and E. Friedman Stimulated D(1) dopamine receptors couple to multiple Galpha proteins in different brain regions J Neurochem 78 2001 981 990
3. K.L. Laugwitz et al. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families Proc Natl Acad Sci U S A 93 1996 116 120
4. S.S. Ferguson Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling Pharmacol Rev 53 2001 1 24
5. S.A. Laporte et al. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis Proc Natl Acad Sci U S A 96 1999 3712 3717
6. T. Kenakin, and M. Williams Defining and characterizing drug/compound function Biochem Pharmacol 87 2014 40 63
7. L.M. Luttrell Minireview More than just a hammer: ligand 'bias' and pharmaceutical discovery Mol Endocrinol 2014 p. me 20131314
8. S.M. DeWire, and J.D. Violin Biased ligands for better cardiovascular drugs Circ Res 109 2011 205 216
9. M. Busnelli et al. Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes J Biol Chem 287 2012 3617 3629
10. A. Bock et al. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling Nat Commun 3 2012 1044
11. E.L. Maillet et al. A novel: conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties FASEB J 21 2007 2124 2134
12. T. Kenakin Functional selectivity and biased receptor signaling J Pharmacol Exp Ther 336 2011 296 302
13. M. Azzi et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors Proc Natl Acad Sci U S A 100 2003 11406 11411
14. J.G. Baker, I.P. Hall, and S.J. Hill Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling Mol Pharmacol 64 2003 1357 1369
15. J.D. Violin, X.R. Ren, and R.J. Lefkowitz G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer J Biol Chem 281 2006 20577 20588
16. S. Galandrin, and M. Bouvier Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy Mol Pharmacol 70 2006 1575 1584
17. J.W. Wisler et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling Proc Natl Acad Sci U S A 104 2007 16657 16662
18. J.J. Liu et al. Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR Science 335 2012 1106 1110
19. K.N. Nobles et al. Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin Sci Signal 4 2011 ra51
20. J.J. DiNicolantonio et al. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol: bisoprolol, metoprolol, and nebivolol) Am J Cardiol 111 2013 765 769
21. T. Noma et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection J Clin Invest 117 2007 2445 2458
22. D.W. Cockcroft Clinical concerns with inhaled beta2-agonists: adult asthma Clin Rev Allergy Immunol 31 2006 197 208
23. K.J. Broadley Beta-adrenoceptor responses of the airways: for better or worse? Eur J Pharmacol 533 2006 15 27
24. L.P. Nguyen et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model Am J Respir Cell Mol Biol 38 2008 256 262
25. L.P. Nguyen et al. Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model Proc Natl Acad Sci U S A 106 2009 2435 2440
26. J.K. Walker et al. Beta-arrestin-2 regulates the development of allergic asthma J Clin Invest 112 2003 566 574
27. L.M. Bohn, M.M. Belcheva, and C.J. Coscia Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells J Neurochem 74 2000 574 581
28. M.R. Bruchas et al. Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes J Biol Chem 281 2006 18081 18089
29. M.R. Bruchas et al. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria J Neurosci 27 2007 11614 11623
30. L.M. Bohn, M.M. Belcheva, and C.J. Coscia Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade J Neurochem 74 2000 564 573
31. G.P. McLennan et al. Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways J Neurochem 107 2008 1753 1765
32. L. Zhou et al. Development of functionally selective: small molecule agonists at kappa opioid receptors J Biol Chem 288 2013 36703 36716
33. M.L. Rives et al. 6′-Guanidinonaltrindole (6′-GNTI) is a G protein-biased kappa-opioid receptor agonist that inhibits arrestin recruitment J Biol Chem 287 2012 27050 27054
34. C.L. Schmid et al. Functional selectivity of 6′- guanidinonaltrindole (6'-GNTI) at kappa-opioid receptors in striatal neurons J Biol Chem 288 2013 22387 22398
35. M.A. Ansonoff, P.S. Portoghese, and J.E. Pintar Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands Psychopharmacology (Berl) 210 2010 161 168
36. B.L. Kieffer Opioids: first lessons from knockout mice Trends Pharmacol Sci 20 1999 19 26
37. K.M. Raehal, J.K. Walker, and L.M. Bohn Morphine side effects in beta-arrestin 2 knockout mice J Pharmacol Exp Ther 314 2005 1195 1201
38. L.M. Bohn et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2 Science 286 1999 2495 2498
39. C.H. Yang et al. Antinociceptive potentiation and attenuation of tolerance by intrathecal beta-arrestin 2 small interfering RNA in rats Br J Anaesth 107 2011 774 781
40. Y. Li et al. Improvement of morphine-mediated analgesia by inhibition of beta-arrestin 2 expression in mice periaqueductal gray matter Int J Mol Sci 10 2009 954 963
41. X.-T. Chen et al. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2- [(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4,5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain J Med Chem 56 2013 8019 8031
42. S.M. DeWire et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine J Pharmacol Exp Therap 344 2013 708 717
43. D.D. Marciniuk et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline Can Respir J 18 2011 69 78
44. D.J. Janssen et al. Symptoms: comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure J Palliat Med 14 2011 735 743
45. D.G. Soergel et al. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers J Clin Pharmacol 54 2014 351 357
46. D.L. Saunders et al. Assessment of the relative potency of fentanyl buccal tablet to intravenous morphine in healthy volunteers using a thermally induced hyperalgesia pain model J Clin Pharmacol 52 2012 870 879
47. J.T. Fitzsimons Angiotensin, thirst, and sodium appetite: retrospect and prospect Fed Proc 37 1978 2669 2675
48. L.T. Skeggs et al. The biochemistry of the renin-angiotensin system and its role in hypertension Am J Med 60 1976 737 748
49. Z. Gaborik et al. The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling Endocrinology 144 2003 2220 2228
50. H. Wei et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 Proc Natl Acad Sci U S A 100 2003 10782 10787
51. K. Rakesh et al. beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress Sci Signal 3 2010 ra46
52. K. Rajagopal et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes Proc Natl Acad Sci U S A 103 2006 16284 16289
53. S. Ahn et al. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor J Biol Chem 279 2004 35518 35525
54. S. Ahn et al. {beta}-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation J Biol Chem 284 2009 8855 8865
55. M. Aplin et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes Basic Clin Pharmacol Toxicol 100 2007 296 301
56. S.M. DeWire et al. Beta-arrestin-mediated signaling regulates protein synthesis J Biol Chem 283 2008 10611 10620
57. D.L. Hunton et al. Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis Mol Pharmacol 67 2005 1229 1236
58. A. Sauliere et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity Nat Chem Biol 8 2012 622 630
59. R.T. Strachan et al. Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR) J Biol Chem 2014
60. J.D. Violin et al. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance J Pharmacol Exp Therap 335 3 2010 572 579
61. G. Boerrigter et al. TRV120027: a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure Circ Heart Fail 5 2012 627 634
62. G. Boerrigter et al. Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure Circ Heart Fail 4 2011 770 778
63. K.S. Kim et al. beta-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury Am J Physiol Heart Circ Physiol 303 2012 H1001 H1010
64. M.M. Monasky et al. The beta-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium Am J Physiol Heart Circ Physiol 305 2013 H856 H866
65. D. Soergel et al. TRV027, a beta-arrestin biased ligand at the angiotensin 2 type 1 receptor, produces rapid, reversible changes in hemodynamics in patients with stable systolic heart failure J Am College Cardiol 61 2013 E683-E683
66. K.M. Raehal et al. Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance Pharmacol Rev 63 2011 1001 1019
67. T. Kenakin, and A. Christopoulos Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat Rev Drug Discov 12 2013 205 216
68. T. Kenakin et al. A simple method for quantifying functional selectivity and agonist bias ACS Chem Neurosci 3 2012 193 203
69. S. Rajagopal et al. Quantifying ligand bias at seven-transmembrane receptors Mol Pharmacol 80 3 2011 367 377